Zacks Investment Research on MSN9d
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage StudyShares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback